<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919850</url>
  </required_header>
  <id_info>
    <org_study_id>1209/151217</org_study_id>
    <nct_id>NCT04919850</nct_id>
  </id_info>
  <brief_title>Effect of 60-days Saccharomyces Boulardii and Superoxide Dismutase Supplementation in Obese Adults</brief_title>
  <official_title>Effect of 60-days Saccharomyces Boulardii and Superoxide Dismutase Supplementation on Body Composition, Hunger Sensation, Pro/Antioxidant Ratio, Inflammation and Hormonal Lipo-metabolic Biomarkers in Obese Adults: a Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda di Servizi alla Persona di Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda di Servizi alla Persona di Pavia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In animals it has been demonstrated that Saccharomyces boulardii decrease low-grade&#xD;
      inflammation and fat mass; also Superoxide Dismutase (SOD) decrease low-grade inflammation.&#xD;
      Therefore, the aim of this double-blind, placebo-controlled clinical trial was to assess the&#xD;
      effect of a 60-days S. boulardii and SOD supplementation on circulating markers of&#xD;
      inflammation, body composition, hunger sensation, pro/antioxidant ratio, hormonal, lipid&#xD;
      profile, glucose, insulin and HOMA-IR, in obese adults (BMI 30-35 kg/m2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Actual">June 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change on concentration of biochemical parameters for hunger sensation and hormonal status</measure>
    <time_frame>Changes from baseline biochemical parameters for hunger sensation and hormonal status at 8 weeks</time_frame>
    <description>Ghrelin (pg/mL), Adiponectin (pg/ml), Peptide YY (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on concentration of biochemical parameters for hunger sensation and hormonal status</measure>
    <time_frame>Changes from baseline biochemical parameters for hunger sensation and hormonal status at 8 weeks</time_frame>
    <description>Leptin (ng/cL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on concentration of biochemical parameters for hunger sensation and hormonal status</measure>
    <time_frame>Changes from baseline biochemical parameters for hunger sensation and hormonal status at 8 weeks</time_frame>
    <description>glucagon-like peptide - 1 (pmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on concentration of biochemical parameters for glico-metabolic status</measure>
    <time_frame>Changes from baseline biochemical parameters for glico-metabolic status at 8 weeks</time_frame>
    <description>Total cholesterol (mg/dL), Low Density Lipoprotein cholesterol (mg/dL), HDL cholesterol (mg/dL), Triglycerides (mg/dL), Apolipoprotein A (mg/dL), Apolipoprotein B (mg/dL), Glycemia (mg/dL), Uric acid (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on concentration of biochemical parameters for glico-metabolic status</measure>
    <time_frame>Changes from baseline biochemical parameters for glico-metabolic status at 8 weeks</time_frame>
    <description>Insulin (mcU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on concentration of biochemical parameters for glico-metabolic status</measure>
    <time_frame>Changes from baseline biochemical parameters for glico-metabolic status at 8 weeks</time_frame>
    <description>Total Proteins (g/dL), Albumin (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on concentration of biochemical parameters for glico-metabolic status</measure>
    <time_frame>Changes from baseline biochemical parameters for glico-metabolic status at 8 weeks</time_frame>
    <description>HOMA index (pt)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on state of hunger, fullness, desire to eat, satiety and prospective food consumption</measure>
    <time_frame>Changes from baseline state of hunger, fullness, desire to eat, satiety and prospective food consumption at 8 weeks</time_frame>
    <description>Eating motivation Visual Analogue Scale (pt): a scale from 0 to 10 points. The scale of hunger (question: &quot;how hungry are you?&quot;) ranged from the answer &quot;not at all&quot; to &quot;as hungry as I have ever felt&quot;; the scale of fullness (question: &quot;how full are you?&quot;) ranged from the answer &quot;not at all&quot; to &quot;as full as I ever felt&quot;; the scale of satiety (question: &quot;how satiated are you?&quot;) ranged from &quot;not at all&quot; to &quot;extremely&quot;; the scale of desire (question: &quot;how strong is your desire to eat?&quot;) ranged from &quot;very weak&quot; to &quot;very strong&quot;; the scale of prospective consumption (question: &quot;how much do you think you could (or would want to) eat right now) ranged from &quot;nothing at all&quot; to &quot;a very large amount&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on concentration of biochemical parameters for nutritional status</measure>
    <time_frame>Changes from baseline biochemical parameters for nutritional status at 8 weeks</time_frame>
    <description>Iron (µg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on concentration of biochemical parameters for hormonal status</measure>
    <time_frame>Changes from baseline biochemical parameters for hormonal status at 8 weeks</time_frame>
    <description>Thyroid Stimulating Hormone (µU/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on concentration of biochemical parameters for inflammation and cardiovascular risk</measure>
    <time_frame>Changes from baseline biochemical parameters for inflammation and cardiovascular risk at 8 weeks</time_frame>
    <description>C-Reactive Protein (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on concentration of biochemical parameters for inflammation and cardiovascular risk</measure>
    <time_frame>Changes from baseline biochemical parameters for inflammation and cardiovascular risk at 8 weeks</time_frame>
    <description>Tumor Necrosis Factor-α (pg/mL), Inter Leukin-1β (pg/mL), Inter Leukin-6 (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on concentration of biochemical parameters for inflammation and cardiovascular risk</measure>
    <time_frame>Changes from baseline biochemical parameters for inflammation and cardiovascular risk at 8 weeks</time_frame>
    <description>Trimethylamine (µM), Trimethylamine-N-oxide (µM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on concentration of biochemical parameters for safety</measure>
    <time_frame>Changes from baseline biochemical parameters for safety at 8 weeks</time_frame>
    <description>Aspartate amino transferase (U/L), Alanine amino transferase (U/L), Gamma Glutamyl Transferase (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on concentration of biochemical parameters for safety</measure>
    <time_frame>Changes from baseline biochemical parameters for safety at 8 weeks</time_frame>
    <description>Creatinine (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on rate of anthropometric measures</measure>
    <time_frame>Changes from baseline anthropometric measures at 8 weeks</time_frame>
    <description>Height (cm), waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on rate of anthropometric measures</measure>
    <time_frame>Changes from baseline anthropometric measures at 8 weeks</time_frame>
    <description>Weight (Kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on rate of anthropometric measures</measure>
    <time_frame>Changes from baseline anthropometric measures at 8 weeks</time_frame>
    <description>Body mass index (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on rate of body composition</measure>
    <time_frame>Changes from baseline body composition at 8 weeks</time_frame>
    <description>Free Fat Mass (kg), Fat Mass (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on rate of body composition</measure>
    <time_frame>Changes from baseline body composition at 8 weeks</time_frame>
    <description>Android fat (%), Gynoid fat (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on rate of body composition</measure>
    <time_frame>Changes from baseline body composition at 8 weeks</time_frame>
    <description>Visceral Adipose Tissue (g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on status of mood assessment</measure>
    <time_frame>Changes from baseline mood assessment at 8 weeks</time_frame>
    <description>Beck questionnaire (pt). The questionnaire is divided into 21 items which have a score from 0 to 3. A total score &gt; 17 indicates borderline depression; &gt; 21 moderate depression; &gt; 31 severe depression; &gt; 40 extreme depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on status of assessment of food preferences</measure>
    <time_frame>Changes from baseline assessment of food preferences at 8 weeks</time_frame>
    <description>Food Frequency Questionnaire (pt). Participants must indicate the consumption of 18 common food items, choosing one between &quot;yes&quot; or &quot;no, never&quot;. Participants were also asked to estimate their usual rate of consumption, choosing from seven categories of frequency, ranging from ''never'' or ''less than once a week'' to ''seven times per week&quot;. The only exception was constituted by the item &quot;coffee consumption&quot;, which is reported as &quot;cups/day&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Obesity</condition>
  <condition>Superoxide Dismutase</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharomyces boulardii and SOD</intervention_name>
    <description>A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  I class of obesity (BMI: 30-35 Kg/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  evidence of heart, kidney or liver disease&#xD;
&#xD;
          -  diagnosis of major depressive disorder&#xD;
&#xD;
          -  current medications for weight loss, for control of cholesterol and triglycerides&#xD;
&#xD;
          -  anti-inflammatory treatments&#xD;
&#xD;
          -  pregrancy of lactation&#xD;
&#xD;
          -  type 1 diabetes mellitus, intestinal inflammatory bowel disease, celiac disease,&#xD;
             chronic pancreatitis&#xD;
&#xD;
          -  probiotic/prebiotic treatment in the last 4 weeks&#xD;
&#xD;
          -  antibiotic use within the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda di Servizi alla Persona</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda di Servizi alla Persona di Pavia</investigator_affiliation>
    <investigator_full_name>Mariangela Rondanelli</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

